Home » Maximilian Hunt

Maximilian Hunt

Senior Principal, Value, Access, and Pricing

Mr. Hunt is a Senior Principal in CBPartners’ Value, Access, and Pricing practice. His experience as a global life sciences strategy consultant spans all stages of product development and a wide range of therapeutic areas, including oncology, inflammatory conditions, cardiovascular diseases, respiratory illnesses, and orphan diseases.

In his time at CBPartners, Mr. Hunt’s engagement work has targeted a variety of commercial business issues related to pricing, access, and value with a focus in pricing and market access strategy in the U.S. and other global developed markets. Mr. Hunt is devoted to delivering innovative and impactful commercial strategy recommendations to biopharmaceutical manufacturers working to navigate the evolving global payer marketplace.

Prior to joining CBPartners, Mr. Hunt worked in the strategy consulting division of Leerink Partners. Mr. Hunt holds a BS in Biomedical Engineering from Johns Hopkins University.

Connect with Maximilian Hunt


+1 904 553 7784


Published Articles

The COVID-19 Pandemic: Pricing and Access Outlook for Future Innovative Drugs in Europe

Disruption in healthcare systems across Europe is rife due to the COVID-19 pandemic, with increasingly strained budgets, and shifting healthcare priorities.

The Cancer Drugs Fund: Paving the Way for Earlier and More Sustainable Access to Promising New Drugs

In 2011, The Cancer Drugs Fund (CDF) was launched to help patients in England access cancer drugs that had been rejected by the NHS. CBPartners' European Center of Excellence discusses the benefits of early engagement with NICE for both manufacturers and patients alike.

Fecal Transplant Treatment: The Messy Pathway to Reimbursement

Life sciences research continues to expand into new domains in the pursuit of innovative therapies. Along with this expansion comes a need for new regulations to ensure efficient and safe use of novel products. In the case of microbiome and fecal transplant therapeutics, the regulatory landscape is still uncertain, creating divergent outlooks for both patients and manufacturers alike. CBPartners has explored the pros and cons of different regulatory approaches, in order to better understand the balance of factors that will determine the future for this exciting area of research.

NICE Invites Pharma to Start the Conversation Early, with a View Towards Shifting Away from ‘No’ as the Starting Point